FCCC LOGO Faculty Publications
Janne PA , von Pawel J , Cohen RB , Crino L , Butts CA , Olson SS , Eiseman IA , Chiappori AA , Yeap BY , Lenehan PF , Dasse K , Sheeran M , Bonomi PD
Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non-small-cell lung cancer
Journal of Clinical Oncology. 2007 Sep;25(25) :3936-3944
PMID: ISI:000249416000024   
Back to previous list
Purpose To evaluate the efficacy of the pan-ERBB inhibitor, CI- 1033, in platinum- refractory or recurrent advanced-stage non-small-cell lung cancer ( NSCLC). Patients and Methods This open-label, randomized phase II trial evaluated CI- 1033 in patients with advanced- stage NSCLC who experienced treatment failure after or were refractory to platinum- based chemotherapy. Three oral CI- 1033 doses were evaluated in 21- day dosing cycles: 50 mg daily for 21 consecutive days, 150 mg daily for 21 consecutive days, and 450 mg daily for 14 consecutive days followed by 7 days of no treatment. The primary efficacy end point was the 1- year survival rate. Results One hundred sixty-six patients were randomly assigned to treatment. Baseline patient demographics were well balanced. The most common drug- related adverse events were rash and diarrhea. The 450- mg arm ( 14 days on/ 7 days off) was closed early due to an excessive rate of adverse events. The 1- year survival rates were 29%, 26%, and 29%, respectively, in the three arms. The response rates were 2%, 2%, and 4%, and stable disease was confirmed in 16%, 23%, and 18% of patients, respectively, in the three study arms. Exploratory analyses demonstrated a prolonged survival in patients who developed a rash and in those with baseline tumor ERBB-2 expression. Conclusion CI- 1033 had modest activity in unselected NSCLC patients but did not meet its primary end point. Future studies should focus on identifying methods of patient selection.
ISI Document Delivery No.: 209VL Times Cited: 0 Cited Reference Count: 39 Cited References: BAILEY R, 2003, LUNG CANCER, V41, P71 BARBACCI EG, 2003, CANCER RES, V63, P4450 BRABENDER J, 2001, CLIN CANCER RES, V7, P1850 BREATHNACH OS, 2001, J CLIN ONCOL, V19, P1734 BURTNESS B, 2005, J CLIN ONCOL, V23, P8646 CALVO E, 2004, CLIN CANCER RES, V10, P7112 CAPPUZZO F, 2005, J CLIN ONCOL, V23, P5007 CAPPUZZO F, 2005, J NATL CANCER I, V97, P643 CITRI A, 2002, EMBO J, V21, P2407 CLAMON G, 2005, CANCER, V103, P1670 DETRE S, 1995, J CLIN PATHOL, V48, P876 FONTANINI G, 1998, CLIN CANCER RES, V4, P241 FRY DW, 1998, P NATL ACAD SCI USA, V95, P12022 FUJIMOTO N, 2005, CANCER RES, V65, P11478 FUKUOKA M, 2003, J CLIN ONCOL, V21, P2237 HERBST RS, 2005, J CLIN ONCOL, V23, P5578 HIRSCH FR, 2002, BRIT J CANCER, V86, P1449 HIRSCH FR, 2005, J CLIN ONCOL, V23, P6838 JANNE PA, 2004, LUNG CANCER-J IASLC, V44, P221 KOBAYASHI S, 2005, NEW ENGL J MED, V352, P786 KRIS MG, 2003, JAMA-J AM MED ASSOC, V290, P2149 KRUG LM, 2005, CANCER, V104, P2149 KWAK EL, 2005, P NATL ACAD SCI USA, V102, P7665 LAI WW, 2001, ANN THORAC SURG, V72, P1868 LANGER CJ, 2004, J CLIN ONCOL, V22, P1180 LYNCH TJ, 2004, NEW ENGL J MED, V350, P2129 MILLER VA, 2004, J CLIN ONCOL, V22, P1103 NEMUNAITIS J, 2005, CLIN CANCER RES, V11, P3846 PAEZ JG, 2004, SCIENCE, V304, P1497 PAO W, 2004, P NATL ACAD SCI USA, V101, P13306 PEREZSOLER R, 2004, J CLIN ONCOL, V22, P3238 RUSCH V, 1993, CANCER RES, V53, P2379 RUSCH V, 1997, CLIN CANCER RES, V3, P515 SHEPHERD FA, 2005, NEW ENGL J MED, V353, P123 THATCHER N, 2005, LANCET, V366, P1527 THERASSE P, 2000, J NATL CANCER I, V92, P205 TSAO MS, 2005, NEW ENGL J MED, V353, P133 WAKELING AE, 2002, CANCER RES, V62, P5749 YI ES, 1997, MODERN PATHOL, V10, P142